Platelet factor 4: An inhibitor of angiogenesis
Platelet factor 4: An inhibitor of angiogenesis
复制标题
DOI：
10.1055/s-2004-831051
复制
发表时间：
2004-06-01
影响因子：
5.7
通讯作者：
Bikfalvi, A
中科院分区：
文献类型：
--
作者：
Bikfalvi, A
血小板因子4（PF 4）是一种抗血管生成ELR阴性趋化因子。PF 4在体内外抑制内皮细胞增殖和迁移以及血管生成。有三种不同的机制被提出来解释PF 4的抗血管生成作用。首先，PF 4可能结合蛋白多糖并干扰蛋白多糖对生长因子活性的旁观者效应。其次，PF 4能够直接与血管生成生长因子如成纤维细胞生长因子或血管内皮生长因子相互作用，并抑制它们与细胞表面受体的相互作用。第三，PF 4可激活内皮细胞上的细胞表面受体并诱导抑制信号。最近，发现了一种这样的受体CXCR 3-B。在心血管疾病中，PF 4可能参与侧支血管形成、斑块新生血管形成、肝素诱导的血小板减少和支架内皮化。几个PF 4片段，如PF 4-CTF和修饰的分子已被制成，表现出抗血管生成的特性，并可能作为进一步的治疗开发的线索。
Platelet factor 4 (PF4) is an antiangiogenic ELR-negative chemokine. PF4 inhibits endothelial cell proliferation and migration and angiogenesis in vitro and in vivo. Three different mechanisms have been proposed to explain PF4's antiangiogenic effects. First, PF4 may bind proteoglycans and interfere with the proteoglycan-bystander effect on growth factor activity. Second, PF4 is able to interact directly with angiogenesis growth factors such as fibroblast growth factors or vascular endothelial growth factors and inhibits their interaction with cell surface receptors. Third, PF4 may activate cell surface receptors on endothelial cells and induce inhibitory signals. Recently, one such receptor, CXCR3-B, was identified. In cardiovascular disease, PF4 may possibly intervene in collateral vessel formation, plaque neovascularization, heparin-induced thrombocytopenia and stent endothelialization. Several PF4 fragments such as PF4-CTF and modified molecules have been made that exhibit antiangiogenesis properties and may serve as leads for further therapeutic development.